Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bioniz Therapeutics
With
Celerion
This is a open-label study of single doses of intravenous BNZ132-1-40 administered to healthy adult subjects. Subjects are followed for 30 days after treatment for collection of safety, PK and PD data. Cohorts of up to 6 subjects will be enrolled for each dose level.
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
males and non-pregnant, non-lactating females
no ongoing clinically significant medical condition
willing and able to provide informed consent
no use of Rx or OTC medications, other than oral contraceptives
You may not be if
Recent systemic infections
Clinically-significant abnormal clinical labs, ECG or physical examination
